ZCUBE
9.6.2020 08:02:10 CEST | Business Wire | Press release
Zcube, Zambon Research Venture, has launched the fourth edition of Open Accelerator , the international acceleration programme dedicated to startups in the Life Sciences, which seeks to identify and accelerate the best solutions that will shape the future of health. The 2020 Call, focused on digital solutions, is running until the 20th of July. Candidates can apply on the website www.openaccelerator.it
Open Accelerator is looking for innovative, high-tech projects and startups leveraging digital technologies to improve patients’ lives . The best proposals will take part in the acceleration program with the possibility of receiving a seed investment of up to € 100,000 per project.
The 2020 Call for Solutions is preferably targeted at the therapeutic areas of the Central Nervous System and Respiratory, with a particular focus on the 4 technological macro areas: Digital Prevention, Monitoring and Therapeutics; Digital Diagnostics; Virtual Health; Clinical Trials Digitalization.
This year, in an attempt to transform the COVID-19 emergency into a growth opportunity for the healthcare system, ZCube is also presenting the Special Challenge concerning new ways of interaction among healthcare professionals, Industry and the community.
“Open Accelerator is continuing with conviction into its fourth edition, reaffirming its commitment to supporting young startups, helping to transform promising projects into concrete solutions for patients” – comments Elena Zambon, President of Zambon Spa and creator of the accelerator programme – “Digital solutions have never been such a vital support for patients and caregivers as they have at this time. We have direct experience of this through ParkinsonCare, our telenursing service with a human touch. That is why we have decided to dedicate the 2020 Call to digital initiatives. We are convinced that they will be increasingly important in tackling the challenges that lie ahead in terms of health and the system's sustainability. This programme is yet another way in which we are pursuing with conviction our commitment to improving patients' lives, integrating cure and care with a multidisciplinary approach”.
After the closure of the Call, on the 20th of July, the Open Accelerator team in collaboration with a panel of experts will select the startups which between October and November will participate in the intensive 4-week acceleration programme , consisting of tailored online and onsite sessions held in the OpenZone scientific campus just outside Milan .
By taking part in the Open Accelerator programme, the startups will have access to a vast international network of entrepreneurs, scientists, investors, Venture capitalists and Life Sciences professionals. At the end of the programme the most promising projects will be awarded a seed investment of up to € 100,000 . Finally, any possible synergies with the companies of the Zambon Group will be assessed.
“Open Accelerator 2020 Call is one of a kind both- for its focus on digital health technologies and for its pragmatic approach, strongly focused on identifying concrete proposals for delivering solutions to healthcare needs ” - says Fabrizio Conicella, General Manager and Board Member of OpenZone and Zcube - “It is only through the active engagement of existing and prospective partnerships that we will be able to maximize the potential of the proposals we receive and select with a clear objective: to offer to the market innovative solutions that currently don't exist ”.
The initiative also leverages the support of several partners, including Deloitte, Unicredit Start Lab, Premio Marzotto, IQVIA Biotech, Italian Angels for Biotech, Portolano & Cavallo, Bird&Bird, Innogest, Evoleen, HUMA, NINA Capital, and Lifeseeder. Discussions are currently underway with other potential Italian and international partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005658/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom